- 全部删除
- 您的购物车当前为空
ICMT-IN-35(即compound 10n),作为FTPA-triazole类ICMT抑制剂(IC50=0.8 μM),能被哺乳动物细胞吸收并阻断K-Ras膜定位,进而诱导K-Ras错定位。ICMT-IN-35对ICMT+/+MEF细胞表现出选择性细胞毒性,对转移性胰腺癌细胞系展示低微摩尔级别活性(IC50=0.8 μM)。
ICMT-IN-35(即compound 10n),作为FTPA-triazole类ICMT抑制剂(IC50=0.8 μM),能被哺乳动物细胞吸收并阻断K-Ras膜定位,进而诱导K-Ras错定位。ICMT-IN-35对ICMT+/+MEF细胞表现出选择性细胞毒性,对转移性胰腺癌细胞系展示低微摩尔级别活性(IC50=0.8 μM)。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | 待询 | 待询 | |
50 mg | 待询 | 待询 |
ICMT-IN-35 相关产品
产品描述 | ICMT-IN-35 (compound 10n), an ICMT inhibitor with an IC50 value of 0.8 μM, is a FTPA-triazole derivative. It demonstrates cellular uptake by mammalian cells, disrupts K-Ras membrane association, and induces K-Ras mislocalization. Additionally, ICMT-IN-35 exhibits selective cytotoxicity towards ICMT +/+ MEF cells and possesses potent activity against metastatic pancreatic cancer cell lines with an IC 50 of 0.8 μM [1]. |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容